Mon, Jul 14, 2014, 5:39 AM EDT - U.S. Markets open in 3 hrs 51 mins

Recent

% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • interesting article. "Using a miniature model of the human intestine, only a few millimeters in size and made from stem cells, the scientists deactivated a gene in the cells tied to metabolic regulation called FOXO1. Once disabled, the cells began producing insulin. " possibly up ALNYs alley?

    "The method, described today in the journal Nature Communications, raises the possibility of replacing insulin-making pancreatic beta cells lost in diabetics by using a drug to retrain patients’ existing cells. While progress has been made in generating beta cells from stem cells, the method hasn’t yet produced ones with all the needed functions, said Domenico Accili, the study’s lead author. Plus, such cells would require transplantation. "

  • MEDA targets 600 million social media users in China as growth potential increases.

  • Reply to

    ALNY and ARWR New Drug

    by danwebs2014 Jun 20, 2014 10:54 AM

    It looks like they are both partnering with Alpha-1 (it's a reasearch foundation) to address the same illness (AAT Deficiency Liver Disease) using competing delivery platforms. I suppose it could also be a combination of both delivery platforms in one study.... someone call me out if I'm wrong here.
    But it's probably competing platforms in two studies side by side, sharing a control group... otherwise why not mention some form of cooperation between the two companies in the pr's?

    From the Anylam pr:
    New data presented at The Liver Meeting are based on an AAT-targeted siRNA conjugated to an N-acetylgalactosamine (GalNAc) ligand, which is designed to achieve targeted delivery of RNAi therapeutics to hepatocytes through uptake by the asialoglycoprotein receptor. Studies were performed in transgenic mice overexpressing the human Z-AAT protein. Subcutaneous administration of a GalNAc-siRNA conjugate targeting Z-AAT led to dose-dependent knockdown of serum levels of human Z-AAT. A single dose of 3 mg/kg led to greater than 95% knockdown of Z-AAT protein that lasted for greater than two weeks. In a multi-dose experiment, twice-weekly dosing at 0.5 mg/kg led to greater than 90% knockdown.

    From the arrowhead pr:
    "ARC-AAT is designed to inhibit the production of mutant AAT protein in the liver and in preclinical studies it has shown high levels of knockdown with long duration of action. AATD patients express mutant AAT, which can accumulate in hepatocytes and damage the liver. Liver disease associated with Alpha-1 antitrypsin deficiency has no current treatment options and patients can progress to cirrhosis, hepatocellular carcinoma, and may require liver transplant." Arrowhead has developed a novel unlocked nucleobase analog (UNA)-containing RNAi molecule designed for systemic delivery using the Dynamic Polyconjugate (DPC) delivery system.

  • Does anyone have insight into why ALNY and ARWR announced trials for a drug addressing the same disease on the same day at almost the same time.

  • The possible illegal attempt of ALNY in filing patent infringement will hopefully backfire for ALNY and for MERCK. Drawing very companies into a expensive and drawn battle in the courts only helps Big Pharma( Merck) and their surrogate ALNY.

    The fact is not only is it a restraint of trade ( Anti-trust violation) but if it can proven that they knowingly knew there was no patent infringement, then ALNY and Merck will dissolve by their chicanery, if US Attorney General files papers against the two under the Rico statue , for Conspiracy

  • Reply to

    WHY IS THE PRICE SINKING?

    by artusaj Jun 2, 2014 9:43 AM

    The possible illegal attempt of ALNY in filing patent infringement will hopefully backfire for ALNY and for MERCK. Drawing very companies into a expensive and drawn battle in the courts only helps Big Pharma( Merck) and their surrogate ALNY.

    The fact is not only is it a restraint of trade ( Anti-trust violation) but if it can proven that they knowingly knew there was no patent infringement, then ALNY and Merck will dissolve by their chicanery, if US Attorney General files papers against the two under the Rico statue , for Conspiracy.

  • Reply to

    WHY IS THE PRICE SINKING?

    by artusaj Jun 2, 2014 9:43 AM

    sentiment. psychology of the market.... once big pharma/big biotech start the biotech acquisition binge the sentiment should flip very quickly. Seems like they are all content to let the dust settle in the biotech index first.... so who knows when this will begin in earnest. It will probably surprise most people when things turn but it's been painful for those of us holding this spring. Thankfully I am still sitting on a double in ALNY. I wish I could say the same for all my bios...... groan.

  • IT HAS A GREAT PIPELINE.

  • Mast Therapeutics (MSTX) See the SEC filing.

  • Reply to

    ALNY's HBV Program

    by iamidiot001 May 12, 2014 12:20 PM

    going back to 100 PPS.... low Market cap for nice risk/reward

  • ADD and HOLD just a few shares of the fastest growing healthcare stock in the United States and watch your portfolio grow like it’s on steroids.

    Several years ago, Millennium Healthcare (MHCC) modeled their business to align with Obamacare, and now revenues are ready to explode from $1 MILLION PER YEAR to over $200 MILLION PER YEAR.

    This explosive growth is being driven by recently announced contracts with over 400 physician offices and by demand from thousands of additional physicians who are standing in line to sign up with Millennium.

    Millennium’s state-of-the-art cardiovascular and cancer diagnostics for early detection are FREE TO PATIENTS and FULLY PAID TO THE DOCTOR by Medicare and private insurance companies. The patient pays nothing, yet receives the benefit of the best non-invasive early detection tests available.

    With the new Affordable Care Act and complex ICD-10 billing codes, Doctor’s incomes are declining. Millennium HealthCare diagnostics will provide doctors with average additional income of more than $500,000 per year per office.

    Millennium’s offering to physicians is so attractive that over 700 offices have already signed up, 1,000 more offices are in legal and ready to be signed and thousands more are lined up to become a Millennium customer.

    Millennium is now shipping the diagnostics to their customers.

    Millennium shares have been trading between $.60 and $1.50 for the past month and with record sales about to hit the bank, shares have the potential to increase the value of any stock portfolio dramatically.

    Millennium has approximately 70 million shares outstanding and sales contracts that will deliver over $200 million per year. With an industry average price to sales ratio of 6 to 1, Millennium shares are expected to be selling at $12.00 per share in the next 12 months.

    And . . . consider that thousands of additional doctors are in now in line to sign with Millennium that will make these sizeable numbers appear small.

    Sentiment: Strong Buy

  • Reply to

    No Drug on the Market for at least 2 Years

    by hundleyrandy Feb 20, 2014 3:33 PM

    Think about it !
    Henry

    Sentiment: Sell

  • Wish I had more cash!!!

    Sentiment: Strong Buy

  • Dudes. RNAi to reduce LDL cholesterol. 'Nuff said. Just bought more.

    Is there a "stronger"-buy button somewhere?

    Sentiment: Strong Buy

  • Reply to

    No Drug on the Market for at least 2 Years

    by hundleyrandy Feb 20, 2014 3:33 PM

    Think about it !
    Henry

    Sentiment: Strong Sell

  • Checkout ORMP

  • Reply to

    Short term and Q4 catalysts

    by thirdmeinvestor Apr 12, 2014 6:33 PM

    Looks to be a good week.

  • PURE Bioscience (PURE) found a new use for biotech that can quickly and safely kill pathogens that are dangerous to humans such as MRSA, influenza, HIV, E.coli, Salmonella, Norovirus, Hepatitis, Pneumonia, colds, Polio, deadly fungus, and most common infectious diseases.

    AND THE SOLUTION IS SAFE, FAST, CHEAP AND EASY.

    PURE Bioscience developed HEAVILY PATENTED “SDC” THAT KILLS ALL THE ABOVE-MENTIONED PATHOGENS AND YET IS PERFECTLY SAFE.

    SDC is Silver Dihydrogen Citrate that has been infused with negative ions.

    IT IS SIMPLY WIPED OR SPRAYED ON ANY SURFACE AND IT REMAINS ACTIVE FOR 24 HOURS.

    Over 650 restaurants tested SDC on more than 1,000 data points and compared the efficacy of the chain's current sanitizer with that of PURE Hard Surface disinfectant and sanitizer and SDC was OVER 90% MORE EFFECTIVE.

    SDC has also been successfully tested for food processing of meats and produce to destroy the dangerous pathogens such as E.coli, Salmonella, Norovirus and others and is expected to set the standard in the food industry.

    THE EPA CLASSIFIES SDC WITH THEIR SAFEST RATING OF CATEGORY IV.

    Also important is that SDC does not cause these dangerous pathogens to become resistant like antibiotics.

    The World Health Organization estimates the cost of influenza epidemics to the economy at $71-167 billion per year.

    The CDC estimates that each year, 48 million food borne illnesses from contaminated foods result in over $50 billion in losses from 128,000 hospitalizations, 3,000 deaths and very costly food recalls and lawsuits.

    SDC will appeal to large markets such as the cruise industry, air travel, all public transportation, schools, hospitals, sporting events and essentially ALL PUBLIC PLACES.

    SDC SALES ARE POSITIONED TO EXPLODE and PURE shares are only $1.20.

    Sentiment: Strong Buy

ALNY
57.36-0.49(-0.85%)Jul 11 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Kodiak Oil & Gas Corp.
NYSEFri, Jul 11, 2014 4:02 PM EDT
USG Corporation
NYSEFri, Jul 11, 2014 4:03 PM EDT